An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, andn Clinical Activity of the MEK Inhibitor GSK 1120212 in Subjects with Relapsed or Refractory Leukemias